Thorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.
Thorvardur Halfdanarson, MD
Advertisement
Articles by Thorvardur Halfdanarson, MD
Thorvardur (Thor) Halfdanarson, MD, discusses investigational agents that are being evaluated in patients with colorectal cancer who do not harbor genomic alterations.
Thorvardur (Thor) Halfdanarson, MD, discusses the KEYNOTE-177 trial in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.
Thorvardur (Thor) Halfdanarson, MD, discusses the molecular differences between left- versus right-sided tumors in colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Halfdanarson on Investigational Agents in Driver-Negative CRCSeptember 3rd 2020
Dr. Halfdanarson on the Evolving Role of Immunotherapy in CRCOctober 21st 2020
Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRCSeptember 1st 2020
Advertisement
Advertisement
Trending on OncLive
1
Targeted Therapies, ADCs, and Oral SERD Combos Expand Treatment Possibilities Across Breast Cancer Settings
2
Head and Neck Oncologists Highlight Practice-Informing Research From ASCO 2026
3
Dr Galsky on the Current Roles of Biomarkers in Bladder Cancer
4
Sonrotoclax Plus Zanubrutinib Yields High Undetectable MRD Rates in Treatment-Naive CLL/SLL
5